Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Cytogen, DuPont Merck End Quadramet Agreement.(pain killer)(Brief Article)
- Biopharmaceutical maker Cytogen says it has ended a licensing agreement with DuPont Merck for Quadramet, a pain relief drug for bone cancer patients. The companies recently settled a lawsuit brought by Cytogen after DuPont Merck said it would stop marketing the drug (CW, June 5, p....
- Research articles 1998-06-17
Additional Resources
- Cytogen Corp.(names in The News)(Brief Article)
- CHRISTOPHER P. SCHNITTKER, CPA, joined Cytogen Corp., Princeton, N.J., as Vice President ... CHRISTOPHER P. SCHNITTKER, CPA, joined Cytogen Corp., Princeton, N.J., as Vice President and CFO. Cytogen is a developer and marketer of proprietary and licensed oncology products
- Research articles 2003-11-01
- Cytogen Announces Quarterly Conference Call and Presentation at Acumen BioFin 9th Annual Healthcare Conference
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) will report its third quarter 2007 financial results on Monday November 5, 2007 at approximately 9:00 am Eastern Time ET. Following the announcement, Michael D. Becker, president and chief executive officer of Cytogen, and other members of Cytogen's management team will host a...
- Research articles 2007-10-25
- DRAXIS Serves Notice to Terminate Cytogen's Marketing Exclusivity for BrachySeed in the U.S.
- MISSISSAUGA, ONTARIO, Jan 27, 2003 CCNMatthews via COMTEX DRAXIMAGE Inc., the radiopharmaceutical division of DRAXIS Health Inc. (TSX: DAX; Nasdaq: DRAX), served notice to Cytogen Corporation (Nasdaq: CYTO) on January 24, 2002, that DRAXIMAGE is exercising its rights, under its License and Supply Agreements...
- Research articles 2003-01-27
- Cytogen Moves to Sell Facility.
- CYTOGEN CORPORATION has signed a letter of intent to sell its manufacturing facility. The Princeton, N.J.-based biopharmaceutical company says it is in late-stage discussions and expects to close the transaction shortly. Under the anticipated CYTOGEN CORPORATION has signed...
- Research articles 1999-01-04
- Cytogen to Present at the Acumen BioFin Rodman & Renshaw Global Healthcare Conference
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) today announced that Michael D. Becker, president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference. Cytogen's presentation is scheduled on Tuesday, May 15, 2007 at 9:25 am Central European Time (3:25 am Eastern...
- Research articles 2007-05-08
- Cytogen Announces Definitive Merger Agreement with EUSA PHARMA for $0.62 per Share in Cash
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) today announced that it has entered into a definitive merger agreement with EUSA Pharma Inc., pursuant to which all outstanding shares of the Company will be converted into $0.62 per share in cash, which represents a premium of approximately 35% over the closing...
- Research articles 2008-03-11
- Cytogen Corporation To Participate In UBS Warburg Global Life Sciences Conference In New York
- Cytogen Corporation (Nasdaq: CYTO), a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, today announced that it will be presenting at the UBS Warburg Global Life Sciences Conference held in New York City from Monday, October 7, through Thursday, October 10,...
- Research articles 1970-01-01
- DuPont, Cytogen and Berlex Finalize Quadramet Agreement.
- DUPONT PHARMACEUTICALS Company has finalized a five-year supply agreement with Cytogen Corporation and Berlex Laboratories Inc. regarding the manufacturing of Quadramet (Sanarium Sm 153 lexidronam injection), a product approved in the US and Canada as a pain treatment for cancer. ...
- Research articles 1998-11-23
- Matritech Selects Cytogen to Market and Distribute New Point-of-Care Diagnostic Test for Bladder Cancer in U.S
- Business Editors and Health/Medical Writers BIOWIRE2K NEWTON, Mass. & PRINCETON, N.J.--BW HealthWire--Sept. 17, 2002 NMP22R BladderChekTM superior to current urine test, cytology, and returns results during a patient's doctor office visit Matritech Inc. (NASDAQ: NMPS) and Cytogen Corporation (NASDAQ: CYTO) today announced that they have...
- Research articles 2002-09-17
- Cytogen to Raise $10.1 Million through Private Placement of Common Stock and Warrants
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO), announced today that it has entered into purchase agreements with certain institutional investors for the sale of 5,814,600 shares of its common stock and 2,907,301 warrants to purchase shares of its common stock at a price of $1.74 per share, through a private...
- Research articles 2007-06-29
- Company Profile for Cytogen Corporation
- Founded in 1980, Cytogen is a biopharmaceutical company dedicated to advancing the care of cancer patients by building, developing, and commercializing a portfolio of specialty pharmaceutical products. The Company's specialized sales force currently markets QUADRAMET[R], PROSTASCINT[R], and SOLTAMOX[TM] to the U.S. oncology market. QUADRAMET is approved for the treatment of...
- Research articles 2007-01-19
- Cytogen Receives Nasdaq Notification Related to Minimum Bid Price
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) announced that it has received today notification from The Nasdaq Stock Market Nasdaq that the Company is not in compliance with the $1.00 minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Marketplace Rule 4450a(5). This letter is...
- Research articles 2007-11-05
- Cytogen: The Wall Street Analyst Forum Presentation Transcript
- Question-and-Answer SessionUnidentified Audience Member [Inaudible Question] Kevin Bratton The question is how many physicians have we seen in our efforts right now to launch CAPHOSOL? I am not sure I have an exact number of that. We have gone to a number of shows and attended...
- Earnings calls 2007-09-20
- Cytogen Corporation [CYTO], New York Yankees Legend Lou Piniella, American Cancer Society, Nation Prostate Cancer Coalition and Prostate Cancer Foundation to Open The NASDAQ Stock Market
- What: Michael Becker, President and Chief Executive Officer of Cytogen Corporation (NASDAQ: CYTO), Lou Piniella, Tampa Bay Devil Rays' manager and former New York Yankee, along with advocates from three leading patient organizations will preside over The NASDAQ Market Open. Where: NASDAQ MarketSite -- 4 Times Square...
- Research articles 2004-09-08
- DRAXIMAGE And Cytogen Agree To End BrachySeed Agreements.
- MISSISSAUGA, ONTARIO, Apr 8, 2003 CCNMatthews via COMTEX DRAXIMAGE now marketing BrachySeedR implants directly to customers in U.S. DRAXIMAGE Inc., the radiopharmaceutical division of DRAXIS Health Inc. (TSX: DAX; Nasdaq: DRAX), has reached an amicable agreement with Cytogen Corporation (Nasdaq: CYTO)...
- Research articles 2003-04-08
- Cytogen Corporation's Auditors Expressed Going-Concern Qualification
- PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) announced today that in its 2007 financial statements included in the Company's Annual Report on Form 10-K, the audit opinion of KPMG LLP contained a "going concern" qualification. NASDAQ's marketplace rules require NASDAQ-listed companies to publicly announce the receipt of an audit opinion...
- Research articles 2008-03-20
- Cytogen Receives Notification By Nasdaq Regarding Marketplace Rule 4450(a)(5)
- Cytogen Corporation (Nasdaq: CYTO), a biopharmaceutical company with an established and growing product line in oncology, today announced that it has been notified by The Nasdaq Stock Market, Inc. that the Company's common stock has closed for more than 30 consecutive trading days below the minimum $1.00 per share requirement...
- Research articles 1970-01-01
- New Data for Cytogen's QUADRAMET® Reported at Annual ASCO Meeting
- Clinical data support feasibility and tolerability of repetitive simultaneous administration of QUADRAMET with docetaxel for prostate cancer patients CHICAGO -- Cytogen Corporation (NASDAQ: CYTO) today reported results from clinical trials demonstrating that QUADRAMET (samarium Sm-153 lexidronam injection) can be safely administered to prostate cancer patients who are also receiving...
- Research articles 2007-06-04
- Transatlantic speciality pharma firm EUSA Pharma is acquiring the US oncology and pain control specialist Cytogen for $22.6m
- Transatlantic speciality pharma firm EUSA Pharma is acquiring the US oncology and pain control specialist Cytogen for $22.6m. EUSA, founded in 2006, is supported by a consortium of life science capital investors including TVM Capital, which has recently led a $50m financing round for EUS& Essex Woodlands, 3i, Goldman Sachs,...
- Research articles 2008-04-07
- << Previous
- page 1 of 1
- Next >>
Presented by American Express